Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Director/PDMR Shareholding

12 Mar 2019 17:23

RNS Number : 6573S
Cambridge Cognition Holdings PLC
12 March 2019
 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Director/PDMR Shareholdings

Further to the Fundraising announced on 7 March 2019, Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, confirms the following disclosures by persons discharging managerial responsibilities.

The information below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Steven Powell

2.

Reason for the Notification

a)

Position/status

PDMR - Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each

Identification code

GB00B8DV9647

b)

Nature of the transaction

Subscription for Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

72p

20,834

d)

Aggregated information:

· Aggregated volume

 

· Price

Subscription for 20,834 ordinary shares at a price of 72p each

e)

Date of the transaction

12 March 2019

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nick Walters

2.

Reason for the Notification

a)

Position/status

PDMR - Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1 pence each

Identification code

GB00B8DV9647

b)

Nature of the transaction

Subscription for Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

72p

13,889

d)

Aggregated information:

· Aggregated volume

 

· Price

Subscription for 13,889 ordinary shares at a price of 72p each

e)

Date of the transaction

12 March 2019

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

Enquiries

Cambridge Cognition Holdings PLC

Steven Powell, Chief Executive Officer

Nick Walters, Chief Financial Officer

 

 

Tel: 01223 810 700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Manasa Patil

 

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

 

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Graham Herring / Miles Nolan / Zach Cohen

Tel: 020 3934 6630

 

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and reduce global R&D and healthcare costs.

 

For further information visit www.cambridgecognition.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDLLFFKXFLBBB
Date   Source Headline
1st Jun 20267:00 amRNS-RCOG to present at Mello 2026
28th May 20261:15 pmRNSLaunch of brain health study with Oura
21st May 20262:50 pmRNSResult of AGM
24th Apr 20263:16 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSResults for the year ended 31 December 2025
7th Apr 20267:01 amRNSNotice of Results
7th Apr 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
1st Apr 20267:00 amRNSBlock Listing Return
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
16th Feb 20267:00 amRNSCommercialisation Agreement
9th Feb 20267:00 amRNSChange of Joint Broker
19th Jan 20267:00 amRNSTrading Update
5th Nov 20257:01 amRNSChange of Auditor
5th Nov 20257:00 amRNSBoard Updates
1st Oct 20257:00 amRNSBlock Listing Return
29th Sep 20257:00 amRNSExercise of Options and Total Voting Rights
26th Sep 20259:59 amRNSHolding(s) in Company
8th Sep 20257:00 amRNSHolding(s) in Company
5th Sep 20252:51 pmRNSHolding(s) in Company
5th Sep 202512:04 pmRNSHolding(s) in Company
2nd Sep 20255:21 pmRNSHolding(s) in Company
1st Sep 202510:58 amRNS-RInvestor Presentation via Investor Meet Company
28th Aug 202510:45 amRNS£1.12m Placing & Subscription, TVR & PDMR Dealings
28th Aug 20257:01 amRNSChanges to Board and Management
28th Aug 20257:00 amRNSInterim Results
19th Aug 202510:10 amRNS-RMonument Therapeutics Partnership with FNIH
12th Aug 20257:00 amRNSLaunch of Speaker Identification Solution
31st Jul 20257:00 amRNSTrading update for period ended 30 June 2025
27th Jun 202512:27 pmRNSResult of AGM
24th Jun 20257:00 amRNS-RMonument Therapeutics Success in Phase I Results
4th Jun 20257:00 amRNSNotice of AGM
6th May 20255:59 pmRNSHolding(s) in Company
1st May 20257:00 amRNSPreliminary Unaudited Results
24th Apr 20257:00 amRNSNotice of Results and Investor Presentation
10th Apr 20257:00 amRNSContract Win
7th Apr 202510:24 amRNSHolding(s) in Company
3rd Apr 20257:00 amRNSContract Win
1st Apr 20257:00 amRNSBlock Listing Return
6th Mar 20257:00 amRNS-RCANTAB® used for major global brain health study
18th Feb 20257:00 amRNS-RCambridge Cognition submits FDA Letter of Intent
7th Feb 20257:00 amRNSBoard Appointment
21st Jan 20257:00 amRNSLaunch of in-house rater training service
16th Jan 20257:00 amRNSExpanded partnership with Actinogen
27th Dec 20243:34 pmRNSDirector/PDMR Share Purchases
23rd Dec 20244:02 pmRNSDirector/PDMR Share Purchases
16th Dec 20249:20 amRNSDirector/PDMR Share Purchases
10th Dec 20247:00 amRNSTrading Update
18th Nov 20244:02 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSMonument Therapeutics secures £1m investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.